Denali Therapeutics Announces First Patient Dosed in Phase 1b Study of DNL747 for Alzheimer’s Disease February 15, 2019
Buoy Health Strategic Partnerships Expand Digital Corporate Benefits Program Options February 13, 2019
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of an Anti-OX40 Antibody February 13, 2019
Castle raises $9.2 million for AI that protects consumer apps from account takeovers February 8, 2019
Orchard Therapeutics Announces Acceptance of Late-Breaking Abstracts of OTL-101 for ADA-SCID and OTL-102 for X-CGD at the 2019 Transplantation and Cellular Therapy Meetings of ASBMT and CIBMTR February 6, 2019
Surface Oncology Retains Worldwide Rights for its First-in-Class Antibody Targeting IL-27, SRF388 February 4, 2019
Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States February 1, 2019